Correction to: CircUBAP2 promotes SEMA6D expression to enhance the cisplatin resistance in osteosarcoma through sponging miR-506-3p by activating Wnt/β-catenin signaling pathway.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed, 36 citations in OpenAlex.

1. Biological role of Semaphorin 6D in the proliferation, migration and invasion of gastric cancer.African health sciences · 2024
   Article
2. Research Progress on the Functions and Mechanism of circRNA in Cisplatin Resistance in Tumors.Frontiers in pharmacology · 2021
   Review

Corrections and comments

• Erratum for
  CircUBAP2 promotes SEMA6D expression to enhance the cisplatin resistance in osteosarcoma through sponging miR-506-3p by activating Wnt/β-catenin signaling pathway.2020

Authors and funding

4 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract